The Drive to Discover Incyte Corporation (Nasdaq:INCY) creates drugs for hematologic and oncology indications, in addition to chronic inflammatory and autoimmune diseases. It currently has several drugs in the pipeline which target such major ailments as Myelofibrosis and Arthritis. According to MarketWatch, the average target price for Incyte is $17, almost $4 higher than its current trading range. With a beta of 2.38, INCY is a fairly volatile stock, and should be researched carefully. Over the past year, shares returned 310%.